The authors present a striking case of a patient experiencing a lichenoid drug eruption secondary to immunotherapy, curiously sparing scarred skin from past burns. We observed vastly higher amounts of inflammatory lymphoid cells staining for PD-1; 70% in skin with a lichenoid drug reaction and 50% in scarred skin. The lack of a lichenoid reaction at sites of scarred skin may indicate that a basement membrane component may be causative for a lichenoid drug eruption.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.14192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lichenoid Drug Eruption Secondary to Apalutamide Treatment.
Cutis
October 2024
Madelyn M. Class is from the Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. Drs. McCoy, Hafeez, and Westheim are from the Department of Dermatology, St. Luke's University Health Network, Easton, Pennsylvania.
A case of probable drug-induced psoriasis to dapagliflozin.
SAGE Open Med Case Rep
November 2024
Division of Dermatology, Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Exposure to certain drugs can trigger new-onset psoriasis or flaring of existing psoriatic disease. The clinical presentation of drug-induced psoriasis can vary, and although there are features suggestive of drug-induced psoriasis, there are currently no standardized criteria to differentiate it from conventional psoriasis. Patients may present with localized psoriasiform plaques, or variants such as palmoplantar, nail disease, or widespread erythroderma.
View Article and Find Full Text PDFCutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution.
Cancers (Basel)
October 2024
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Article Synopsis
- Advanced melanoma treatments have evolved with targeted therapies and immunotherapies, which significantly impact management but also lead to increased skin toxicities during treatment.
- A study in Bologna identified that 37.5% of 202 patients treated for melanoma developed cutaneous adverse events, primarily linked to drugs like ipilimumab and nivolumab.
- Most skin reactions were low-grade and manageable, but some resulted in severe conditions, highlighting the importance of recognizing and treating these toxicities to ensure patient quality of life.
Concurrent Eruptive Melanocytic Nevi and Multiple Keratoacanthomas Induced by Encorafenib.
Cureus
September 2024
Oncology, Biokliniki Athinon, Athens, GRC.
Article Synopsis
- - A case study discusses a 64-year-old male with metastatic colorectal cancer who developed severe itching and new skin lesions after treatment with encorafenib and panitumumab, medications targeting cancer pathways.
- - The patient showed a mix of skin lesions, including benign moles and keratoacanthomas, with further evaluation confirming a link between the skin reactions and the use of encorafenib, as validated by the Naranjo scale.
- - Stopping the medications led to significant improvement in skin lesions, highlighting the importance of ongoing skin assessments for patients on BRAF inhibitors to manage side effects effectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!